The ROS and MAP cohorts have been designed for data and sample sharing, and they have been at the forefront of large-scale omic data generation from the human brain and also of sharing such data through efforts such as the DREAM challenge10 and the AMP-AD research program funded by the National Institute of Aging. Previous reports described the study design and data collection scheme of each study in detail11,12. By October 8, 2017, 3,322 ROSMAP participants (72.7% females) were enrolled and completed the baseline assessment, of which 1,702 (67.3% females) had died and 1,475 (67.2% females) had undergone brain autopsies. The autopsy rate in these studies exceeds 86%, ensuring that the autopsied subjects are representative of the study populations. Tables 1 and 2 outline the demographic and selected diagnostic characteristics of the subjects included for each set of data; they also list the most commonly used phenotypes. Fig. 1 illustrates the extent of subject overlap among the different sets of data. All of the studies were approved by the institutional review board of Rush University, Columbia University, and Partners Healthcare/Broad Institute. Informed consent was received from all participants or their representatives.
